This product is suitable for research use only. There are a number of products that are identified as 'generic' compounds, including those with the SML prefix. However, none of these compounds would be suitable for use as Active Pharmaceutical Ingredients. Unfortunately, these products have not been listed in a single brochure.
SML2014
Deracoxib
≥98% (HPLC)
Sinónimos:
4-[3-(Difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide, 4-[5-(3-Fluoro-4-methoxyphenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, SC-046, SC-46, SC-59046
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
| Talla/SKU | Disponibilidad | Precio |
|---|---|---|
100 mg | Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad | 156,00 € |
Acerca de este artículo
Fórmula empírica (notación de Hill):
C17H14F3N3O3S
Número CAS:
Peso molecular:
397.37
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
156,00 €
Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleassay
≥98% (HPLC)
form
powder
color
white to brown
solubility
DMSO: 2 mg/mL, clear
storage temp.
room temp
SMILES string
FC(F)c1n[n](c(c1)c3cc(c(cc3)OC)F)c2ccc(cc2)[S](=O)(=O)N
InChI
1S/C17H14F3N3O3S/c1-26-16-7-2-10(8-13(16)18)15-9-14(17(19)20)22-23(15)11-3-5-12(6-4-11)27(21,24)25/h2-9,17H,1H3,(H2,21,24,25)
InChI key
WAZQAZKAZLXFMK-UHFFFAOYSA-N
Biochem/physiol Actions
Deracoxib is an orally active cyclooxygenase-2 (COX-2) inhibitor with >48-fold selectivity over COX-1 (IC50 of 203-189 nM against COX-2-dependent PGE2 production vs. IC50 of 9.85-9.96 μM against COX-1-dependent TxB2 production in dog whole blood). Deracoxib is also reported to exhibit inhibitory activity against phosphodiesterase (Ki = 3.6 μM against human PDE4D3) as well as positive modulatory effiacy toward 2-APB-stimulated transient receptor potential vanilloid 3 channel (TRPV3) activity.
Orally active COX-2 inhibitor with >48-fold selectivity over COX-1. Also inhibits PDE4D3 and enhances 2-APB-stimulated TRPV3 activity.
1 of 1
Este artículo | |||
|---|---|---|---|
| description ≥98% (HPLC) | description ≥98% (HPLC) | description ≥98% (HPLC) | description ≥98% (HPLC) |
| assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay ≥98% (HPLC) |
| form powder | form powder | form powder | form powder |
| storage temp. room temp | storage temp. -10 to -25°C | storage temp. 2-8°C | storage temp. room temp |
| solubility DMSO: 2 mg/mL, clear | solubility DMSO: 2 mg/mL, clear | solubility DMSO: 5 mg/mL (warmed, clear solution) | solubility DMSO: 30 mg/mL, clear |
| color white to brown | color white to beige | color white to beige | color white to beige |
Palabra de advertencia
Warning
Códigos de peligro
Indicaciones de precaución
Hazard Classifications
Acute Tox. 4 Oral
Clase de almacenamiento
11 - Combustible Solids
¿Qué está pasando?
WGK 3
Punto de inflamación (°F)
Not applicable
Punto de inflamación (°C)
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
-
SML- portfolio recommended for which segments? Can we offer this to customer as INNs (International Nonproprietary Names) standards. Please also share with us the complete brochure of SML- products.
1 respuesta-
¿Le ha resultado útil?
-